Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Income from Continuing Operations (2024 - 2026)

Prelude Therapeutics' Income from Continuing Operations history spans 3 years, with the latest figure at 14177000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 59.03% to 14177000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 84137000.0, a 39.89% increase, with the full-year FY2025 number at 104566000.0, up 25.16% from a year prior.
  • Income from Continuing Operations hit 14177000.0 in Q1 2026 for Prelude Therapeutics, up from 17348000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for PRLD hit a ceiling of 14177000.0 in Q1 2026 and a floor of 37164000.0 in Q2 2024.
  • Historically, Income from Continuing Operations has averaged 28717444.44 across 3 years, with a median of 33831000.0 in 2024.
  • Biggest five-year swings in Income from Continuing Operations: decreased 0.77% in 2025 and later soared 59.03% in 2026.
  • Tracing PRLD's Income from Continuing Operations over 3 years: stood at 33831000.0 in 2024, then skyrocketed by 48.72% to 17348000.0 in 2025, then increased by 18.28% to 14177000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for PRLD at 14177000.0 in Q1 2026, 17348000.0 in Q4 2025, and 20418000.0 in Q3 2025.